Retatrutide vs Tesamorelin
A comprehensive, data-driven comparison of Retatrutide (LY3437943) and Tesamorelin (Egrifta). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Retatrutide LY3437943 | Tesamorelin Egrifta, TH9507 |
|---|---|---|
| FDA Status | Phase 3 (NDA expected late 2026) | FDA Approved |
| Category | Weight Loss | Growth Hormone |
| Primary Use | Obesity and weight management | HIV-associated lipodystrophy |
| Weight Loss % | 28.7% | N/A |
| Monthly Cost | $1,200 - $1,500/mo | $200 - $1,500/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 12mg weekly (dose escalated from 2mg) | 2mg daily |
| Frequency | Weekly | Daily |
| Mechanism | Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion, reduce appetite, and increase energy expenditure | Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone production |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | High |
| Clinical Trial Phase | Phase 3 | Approved |
Key Differences
- 1Tesamorelin is FDA-approved, while Retatrutide is currently phase 3 (nda expected late 2026).
- 2Retatrutide has clinical weight loss data (28.7%), while Tesamorelin is not primarily indicated for weight loss.
- 3Tesamorelin is generally more affordable ($200 - $1,500/mo) compared to Retatrutide ($1,200 - $1,500/mo).
- 4Retatrutide is dosed weekly, while Tesamorelin is daily.
- 5They belong to different categories: Retatrutide (Weight Loss) vs Tesamorelin (Growth Hormone).
Which Is Better For...
Tesamorelin
Those seeking an FDA-approved treatment with established safety data
Tesamorelin
More budget-friendly option with lower monthly costs
Retatrutide
More convenient dosing schedule (weekly)
Tesamorelin
Fewer commonly reported side effects
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Retatrutide | $1,200 - $1,500/mo | Phase 3 (NDA expected late 2026) | Eli Lilly |
| Tesamorelin | $200 - $1,500/mo | FDA Approved | Theratechnologies |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Retatrutide works via Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion,. Tesamorelin works via Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone. They differ in FDA approval status, efficacy data, and cost.
Retatrutide has demonstrated 28.7% average weight loss in clinical trials. Tesamorelin is not primarily used for weight loss.
Retatrutide typically costs $1,200 - $1,500/mo, while Tesamorelin costs $200 - $1,500/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Retatrutide is not FDA-approved (Phase 3 (NDA expected late 2026)). Tesamorelin is FDA-approved. FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Retatrutide include Nausea, Diarrhea, Vomiting. Common side effects of Tesamorelin include Injection site reactions, Arthralgia, Peripheral edema. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Retatrutide is a novel triple-receptor agonist developed by Eli Lilly currently in Phase 3 clinical trials. It has demonstrated unprecedented weight loss results, with patients losing an average of 28...
View Full Retatrutide GuideTesamorelin is an FDA-approved synthetic growth hormone releasing hormone analog specifically indicated for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. A new weekly reco...
View Full Tesamorelin GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Retatrutide and Tesamorelin should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.